Clinical Trial Update: A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the blood glucose-lowering effect of NN1250 in subjects with Type 2 diabetes has completed its Phase 1 assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NN1250

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED